The global COVID-19 pandemic has highlighted the important role that scalable and flexible manufacturing solutions in enabling rapid response to new disease outbreaks. The pandemic has led the biotech industry to join forces to rapidly develop different vaccine candidates (e.g. mRNA, vector vaccines, protein subunits etc.). Given the scale of the immunization campaigns needed, reaching the correct manufacturing capacity is paramount, hence the scalable and flexible technologies are needed in order to accommodate different process designs while enabling wide access to these vaccines. This presentation will demonstrate how process intensification is used to provide scalable and flexible solutions for cost-effective vaccine manufacture.